William John, M.D.
Senior Medical Fellow, Eli Lily and Company
Dr. John received his medical degree at the University of Kentucky, Lexington, where he became associate medical director at the Markey Cancer Center after his postgraduate training in medical oncology. He later joined Eli Lily and Company where he became associate medical director on the Oncology Platform. He left Eli Lily to work for two years in private practice, then returned to the company where he currently serves as a senior medical fellow.
Dr. John has been integral to the oncology business unit at Eli Lily where he has been the primary physician developing the maintenance indication for Alimta in non-small cell lung cancer (NSCLC). He also was an important part of the group working with histology subgroup efficacy with Alimta in NSCLC, and is the key physician for the next aspect of Alimta’s development with Avastin and in locally advanced NSCLC. Dr. John is now working with abemaciclib in NSCLC.